185 related articles for article (PubMed ID: 28919755)
1. Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma.
Kuai R; Subramanian C; White PT; Timmermann BN; Moon JJ; Cohen MS; Schwendeman A
Int J Nanomedicine; 2017; 12():6581-6594. PubMed ID: 28919755
[TBL] [Abstract][Full Text] [Related]
2. Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer.
Wang T; Subramanian C; Yu M; White PT; Kuai R; Sanchez J; Moon JJ; Timmermann BN; Schwendeman A; Cohen MS
Surgery; 2019 Dec; 166(6):1168-1175. PubMed ID: 31371177
[TBL] [Abstract][Full Text] [Related]
3. Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas.
Subramanian C; Kuai R; Zhu Q; White P; Moon JJ; Schwendeman A; Cohen MS
Surgery; 2016 Jan; 159(1):284-94. PubMed ID: 26582501
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II promotes selective uptake of high density lipoprotein cholesterol esters in bovine adrenal glomerulosa and human adrenocortical carcinoma cells through induction of scavenger receptor class B type I.
Cherradi N; Bideau M; Arnaudeau S; Demaurex N; James RW; Azhar S; Capponi AM
Endocrinology; 2001 Oct; 142(10):4540-9. PubMed ID: 11564720
[TBL] [Abstract][Full Text] [Related]
5. Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins.
Fawaz MV; Kim SY; Li D; Ming R; Xia Z; Olsen K; Pogozheva ID; Tesmer JJG; Schwendeman A
J Pharmacol Exp Ther; 2020 Feb; 372(2):193-204. PubMed ID: 31776208
[TBL] [Abstract][Full Text] [Related]
6. Characterization of apolipoprotein A-I peptide phospholipid interaction and its effect on HDL nanodisc assembly.
Patel H; Ding B; Ernst K; Shen L; Yuan W; Tang J; Drake LR; Kang J; Li Y; Chen Z; Schwendeman A
Int J Nanomedicine; 2019; 14():3069-3086. PubMed ID: 31118623
[No Abstract] [Full Text] [Related]
7. Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting.
Tang J; Kuai R; Yuan W; Drake L; Moon JJ; Schwendeman A
Nanomedicine; 2017 Aug; 13(6):1869-1878. PubMed ID: 28434931
[TBL] [Abstract][Full Text] [Related]
8. Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy.
Gong M; Zhang Q; Zhao Q; Zheng J; Li Y; Wang S; Yuan Y
Drug Deliv; 2019 Dec; 26(1):708-716. PubMed ID: 31290708
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
[TBL] [Abstract][Full Text] [Related]
10. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
[TBL] [Abstract][Full Text] [Related]
11. Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization.
Tang J; Li D; Drake L; Yuan W; Deschaine S; Morin EE; Ackermann R; Olsen K; Smith DE; Schwendeman A
J Lipid Res; 2017 Jan; 58(1):124-136. PubMed ID: 27881716
[TBL] [Abstract][Full Text] [Related]
12. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
[TBL] [Abstract][Full Text] [Related]
13. Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin.
Yuan Y; Wen J; Tang J; Kan Q; Ackermann R; Olsen K; Schwendeman A
Int J Nanomedicine; 2016; 11():6229-6238. PubMed ID: 27920529
[TBL] [Abstract][Full Text] [Related]
14. Preparation of Lipid Nanodisks Containing Apolipoprotein E-Derived Synthetic Peptides for Biocompatible Delivery Vehicles Targeting Low-Density Lipoprotein Receptor.
Tanaka M; Hasegawa M; Yoshimoto N; Hoshikawa K; Mukai T
Biol Pharm Bull; 2019; 42(8):1376-1383. PubMed ID: 31366872
[TBL] [Abstract][Full Text] [Related]
15. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
[TBL] [Abstract][Full Text] [Related]
16. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
17. Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study.
Wu L; Huang X; Kuang Y; Xing Z; Deng X; Luo Z
Drug Des Devel Ther; 2019; 13():2787-2798. PubMed ID: 31496655
[TBL] [Abstract][Full Text] [Related]
18. Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics.
Li D; Fawaz MV; Morin EE; Ming R; Sviridov D; Tang J; Ackermann R; Olsen K; Remaley AT; Schwendeman A
Mol Pharm; 2018 Jan; 15(1):83-96. PubMed ID: 29141139
[TBL] [Abstract][Full Text] [Related]
19. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.
Fiorentini C; Fragni M; Perego P; Vezzoli S; Bonini SA; Tortoreto M; Galli D; Claps M; Tiberio GA; Terzolo M; Missale C; Memo M; Procopio G; Zaffaroni N; Berruti A; Sigala S
J Clin Endocrinol Metab; 2016 Dec; 101(12):4594-4602. PubMed ID: 27626976
[TBL] [Abstract][Full Text] [Related]
20. ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo.
Cheng Y; Kerppola RE; Kerppola TK
Endocr Relat Cancer; 2016 Apr; 23(4):1-19. PubMed ID: 26843528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
